A 40-year-old pregnant woman, she once had a normal birth previously. The pregnancy was a second child, at the age of 17+5, the doctor recommended the iNIPS test.She gave birth to a second child. When she was 17+5 pregnant, her doctor suggested that iNIPS should be performed. No abnormalities were found in chromosome 21, 18 and 13. However, chromosome 2 indicated a fragment abnormal signal (suspected deletion). After amniocentesis, it was confirmed that there was a deletion of the pathogenic fragment on chromosome 2, the couple asked the doctor for genetic counseling in order to develop a corresponding follow-up plan.
Improved Non-invasive Prenatal Testing
Studies have shown that the incidence of chromosomal microdeletions/microduplications in fetuses with normal maternal chromosomes ranges from 1% to 1.7%. Many microdeletions/microduplications can lead to congenital malformations, organ dysfunction, growth retardation, intellectual disability, autism, etc. BaseINIPT is a genetic test designed to assess the risk of fetal chromosomal aneuploidy (Trisomy 21, Trisomy 18, Trisomy 13 etc.) by analyzing maternal peripheral blood, meanwhile, it also can further reduce birth defects by screening 4 sex chromosomes, 7 common chromosomal microdeletions/microduplications syndrome and 86 chromosomal microdeletions/microduplications syndrome ( size over 10M).
Pregnant women concerned about the health of their fetuses
Pregnant women who don't want to do amniocentesis
Serological screening suggests a high risk of pregnancy
Serological screening high-risk pregnant women
Patients with interventional prenatal diagnosis contraindications
Pregnancy 20+6 weeks or more, missed the best time for serological screening
Only peripheral blood is needed, no risks for miscarriage
Test report will be issued within 20 working days
Comprehensive DNA testing, provide over 99% accuracy
Test can be performed at 12 weeks gestational age
Up to 400,000 yuan health insurance to protect patients interests
Lower price benefit from upgraded technology